Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | intermediate filament proteins | 0.003 | 0.3537 | 0.6116 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0017 | 0.0375 | 0.0375 |
Echinococcus granulosus | lamin dm0 | 0.003 | 0.3537 | 1 |
Echinococcus granulosus | lamin | 0.003 | 0.3537 | 1 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0017 | 0.0375 | 0.0375 |
Echinococcus multilocularis | lamin dm0 | 0.003 | 0.3537 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0017 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | hypothetical protein | 0.0029 | 0.3397 | 0.3397 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0037 | 0.5545 | 0.5545 |
Schistosoma mansoni | lamin | 0.003 | 0.3537 | 0.6116 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0017 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | hypothetical protein | 0.0037 | 0.5545 | 0.5545 |
Echinococcus multilocularis | lamin | 0.003 | 0.3537 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0037 | 0.5545 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0055 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.003 | 0.3537 | 0.3537 |
Brugia malayi | intermediate filament protein | 0.003 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | intermediate filament protein | 0.003 | 0.3537 | 0.3537 |
Onchocerca volvulus | 0.003 | 0.3537 | 0.5 | |
Onchocerca volvulus | 0.003 | 0.3537 | 0.5 | |
Echinococcus granulosus | intermediate filament protein | 0.003 | 0.3537 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.003 | 0.3537 | 0.3537 |
Echinococcus multilocularis | musashi | 0.003 | 0.3537 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0055 | 1 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0055 | 1 | 1 |
Schistosoma mansoni | lamin | 0.003 | 0.3537 | 0.6116 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 1.4 uM | Compound concentration required to reduce the cell proliferation of larynx carcinoma cells by 50%, using MTT method. | ChEMBL. | 12431048 |
IC50 (functional) | = 1.4 uM | Compound concentration required to reduce the cell proliferation of larynx carcinoma cells by 50%, using MTT method. | ChEMBL. | 12431048 |
IC50 (functional) | = 3.6 uM | Compound concentration required to reduce the cell proliferation of human acute B-lymphoblastic leukemia CCRF-SB cells by 50%, using MTT method. | ChEMBL. | 12431048 |
IC50 (functional) | = 3.6 uM | Compound concentration required to reduce the cell proliferation of human acute B-lymphoblastic leukemia CCRF-SB cells by 50%, using MTT method. | ChEMBL. | 12431048 |
IC50 (functional) | = 8.2 uM | Compound concentration required to reduce the cell proliferation of cervix carcinoma Hela cells cells by 50%, using MTT method. | ChEMBL. | 12431048 |
IC50 (functional) | = 8.2 uM | Compound concentration required to reduce the cell proliferation of cervix carcinoma Hela cells cells by 50%, using MTT method. | ChEMBL. | 12431048 |
IC50 (functional) | = 9.5 uM | Compound concentration required to reduce the cell proliferation of human CD4+T cells by 50%, using MTT method. | ChEMBL. | 12431048 |
IC50 (functional) | = 9.5 uM | Compound concentration required to reduce the cell proliferation of human CD4+T cells by 50%, using MTT method. | ChEMBL. | 12431048 |
IC50 (functional) | > 50 uM | Compound concentration required to reduce the cell proliferation of human acute T-lymphoblastic leukemia CCRF-CEM cells by 50%, using MTT method. | ChEMBL. | 12431048 |
IC50 (functional) | > 50 uM | Compound concentration required to reduce the cell proliferation of human acute T-lymphoblastic leukemia CCRF-CEM cells by 50%, using MTT method. | ChEMBL. | 12431048 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 12431048 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.